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Edited by Takashi GojoboriAbstract The liver, a major organ for drug metabolism, is phys-
iologically similar between monkeys and humans. However, the
paucity of identiﬁed genes has hampered a deep understanding
of drug metabolism in monkeys. To provide such a genetic re-
source, 28655 expressed sequence tags (ESTs) were generated
from a cynomolgus monkey liver full-length enriched cDNA li-
brary, which contained 23 unique ESTs homologous to human
drug-metabolizing enzymes. Our comparative genomics ap-
proach identiﬁed nine lineage-speciﬁc candidate ESTs, including
three drug-metabolizing enzymes, which could be important for
understanding the physiological diﬀerences between monkeys
and humans.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Cynomolgus monkeys have been used as an animal model
for the investigation of human physiology and disease because
of their close genetic and physiological similarities to humans.
Application of this animal model includes predicting metabolic
fate of newly developed drugs due to pharmacokinetics similar
to humans. However, we now know that diﬀerences in meta-
bolic properties are occasionally seen for some drugs between
monkeys and humans [1–7] possibly due to diﬀerences in ge-
netic components essential for drug metabolism between the
two lineages, such as lineage-speciﬁc genes and alternativelyAbbreviations: CYP, cytochrome P450; EST, expressed sequence tag;
FMO, ﬂavin-containing monooxygenase; GST, glutathione S-trans-
ferase; ORF, open reading frame; SULT, sulfotransferase; UGT,
UDP-glucuronosyltransferase
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doi:10.1016/j.febslet.2007.12.031spliced transcripts. However, limited numbers of lineage-spe-
ciﬁc genes identiﬁed in monkeys have hampered complete
knowledge of lineage diﬀerences in drug metabolism.
An expressed sequence tag (EST)-sequencing approach has
been a rapid and eﬃcient way to identify novel cDNAs that
provide a basis to investigate genetic components essential to
various physiological functions. In non-human primates, ef-
forts have been made for the comprehensive identiﬁcation of
ESTs in chimpanzees [8], rhesus monkeys [9,10], and cynomol-
gus monkeys [11–13]. However, liver tissue has not been exten-
sively sequenced for ESTs, thus only limited genetic
information is available on liver physiological function such
as drug metabolism. With the completion of a draft of the rhe-
sus monkey genome sequence [14], EST analysis of macaques
should be more feasible and accurate.
To provide a monkey genetic resource, 28655 ESTs from
cynomolgus monkey liver were generated. These macaque
ESTs analyzed against the rhesus genome identiﬁed 1064
unique ESTs, most of which (77.0%) matched the human
RefSeq database. cDNAs highly homologous to human
drug-metabolizing genes were identiﬁed, including those of
cytochrome P450 (CYP), UDP-glucuronosyltransferase
(UGT), glutathione S-transferase (GST), sulfotransferase
(SULT), and ﬂavin-containing monooxygenase (FMO). More-
over, our method to select lineage-speciﬁc ESTs successfully
identiﬁed novel transcripts related to drug metabolism. This
genetic information should help in discerning various physio-
logical characteristics, including drug metabolism in monkeys.2. Materials and methods
2.1. cDNA library construction and EST sequencing
Liver samples were collected from three adult cynomolgus monkeys
(two males and one female) and used to generate a full-length enriched
cDNA library using the pME18S-FL3 vector by the oligo-capping
method as previously described [15]. Puriﬁed DNA was sequenced
using the ABI PRISM BigDye Terminator Cycle Sequencing Ready
Reaction Kit, Version 2.0 (Applied Biosystems, Foster City, CA),
followed by electrophoresis with ABI-3700 DNA Analyzer (Applied
Biosystems) according to the manufacturers instructions. Primers
(5 0-GGATGTTGCCTTTACTTCTA-3 0 and 5 0-TTTTTTTTTTTT-
TTTTTV-3 0) were used for single-pass sequencing of 5 0 and 3 0-ends
for each cDNA, respectively.blished by Elsevier B.V. All rights reserved.
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Vector sequence was trimmed and sequence quality was inspected
using Phred (University of Washington). Only EST sequences longer
than 200 bases were used. Generated EST sequences were ﬁrst compu-
tationally mapped to theMacaca mulatta genomic sequence (rheMac2,
UCSC Genome Browser). Computational mapping was carried out as
previously described by consequential use of sequence alignment pro-
grams, BLAT and SIM4 [16]. Only ESTs over the entire sequence
length that mapped perfectly at unique positions on the macaque gen-
ome were regarded as ‘‘mapped’’. Further information for each cDNA
is presented in our database, DBTSS (http://dbtss.hgc.jp), and a user
manual has been published [16].
The macaque genomic sequences to which our cynomolgus ESTs
mapped were examined for any corresponding human genomic and
RefSeq sequence. If any, the corresponding macaque EST was corre-
lated with the human RefSeq gene. Based on information from the cor-
related human RefSeq gene, GO (Gene Ontology) classiﬁcation was
carried out for macaque ESTs using GO slim (http://www.geneontolo-
gy.org/) for ‘‘Biological Process’’, Molecular Function’’, and ‘‘Cellular
Component’’.
2.3. Identiﬁcation of putative macaque-speciﬁc transcripts
To identify macaque ESTs that do not match to human genes, the
ESTs were analyzed by either a genome- or cDNA-based approach.
In the genome-based approach, we selected the EST sequence located
outside human-macaque alignable regions according to the genome–
genome alignment in the UCSC Genome Browser. In the cDNA-based
approach, ESTs were ﬁrst searched with the human RefSeq database
using BLASTN (cut-oﬀ = 1.0e100). Those ESTs with no hits were
clustered with each other (cut-oﬀ = 0.0; >98% identity) and clusters
containing more than 10 ESTs were selected. Those clustered cDNAs
were searched against the human RefSeq database again (1.0e50),
and the generated sequence alignments were further manually in-
spected. For the macaque-speciﬁc transcript candidates, complete se-
quences were determined by primer-walking.3. Results and discussion
3.1. Sequencing and clustering of macaque liver ESTs
A full-length cDNA library was constructed from cynomol-
gus monkey (Macaca fascicularis) livers using the oligo-cap-
ping method [15]. One-pass sequencing at 5 0 and 3 0-ends of
the liver cDNA clones and sequence processing generated a
total of 28655 high quality ESTs (deposited in GenBank under
Accession Nos. BB873801–BB902455). Only 3 0 ESTs (27959
entries) were further analyzed. Of these ESTs, 14727 (53%)
were successfully mapped to 1064 diﬀerent regions in the rhe-
sus macaque genome. Of the 1064 regions, 819 (77%) reside in
genomic regions highly homologous to human RefSeq genes as
revealed by a genome–genome comparison, and were anno-Table 1
Genes abundantly expressed in liver (>100 reads)
Contig number ESTs Human RefSeq ID
15043 4354 NM_000477
15223 3763 NM_000509
15577 1097 NM_005141
10429 277 NM_005143
19271 253 NM_000668
17733 245 NM_001085
5070 227 NM_000035
6405 158 NM_016413
5438 154 NM_000638
11141 130 NM_000354
12017 125 NM_001622
15222 109 NM_000508
17083 106 NM_001756tated with human RefSeq genes (Table 1). Clustering of
27959 ESTs was carried out by calculating the number of
ESTs that mapped to the same region, which should represent
the cluster size for the corresponding gene. This analysis for
the 1064 mapped regions in the genome indicated that these
1064 unique ESTs consisted of 525 contigs (49.3%) and 539
singletons (50.7%). The number of members in each cluster
ranged up to 4354, with a 26.9 average. The gene expression
proﬁle based on our EST data reﬂected liver functional charac-
teristics because the most abundantly expressed genes were
hepatocyte-speciﬁc markers, such as albumin, ﬁbrinogen gam-
ma and beta polypeptides, haptoglobin, and alcohol dehydro-
genase, all of which comprised more than half of the identiﬁed
ESTs (Table 1). Such high redundancy of hepatic ESTs from
the non-normalized cDNA libraries has been also seen for
human libraries [17–19].
3.2. Functional classiﬁcation of ESTs
Provisional functional classiﬁcation was carried out using
GO slim terms based on the human RefSeq genes that corre-
lated with our macaque ESTs (Fig. 1). Out of 819 unique ESTs
that matched a human RefSeq entry, 786 (96.0%) were as-
signed to at least one main category; Biological Process,
Molecular Function, and Cellular Component, to which 520,
458, and 373 sequences (48.9%, 43.0%, and 35.1%) were classi-
ﬁed, respectively. Sequences from 133 ESTs (16.2%) were
annotated into all three categories. The largest EST groups in-
clude metabolism, transcription, protein biosynthesis, electron
transport, transport, signal transduction, and lipid metabolism
(Fig. 1A) for Biological Process, and protein binding, transfer-
ase activity, and nucleotide binding for Molecular Function
(Fig. 1B).
3.3. ESTs relevant to drug metabolism
Our major objective was identiﬁcation of cDNAs important
for drug metabolism, namely those encoding drug-metaboliz-
ing enzymes, which belong to CYP, UGT, GST, SULT, and
FMO families. The 446 ESTs in 23 clusters were highly homo-
logous to genes for such drug-metabolizing enzymes in humans
(Table 2). For the CYP family, only ESTs for the CYP1 to
CYP4 subfamilies are indicated in the list because of their
importance in drug metabolism. The CYP family contained
231 entries (51.8%), the largest group among the ESTs for
drug-metabolizing enzymes. CYP, a phase I drug-metabolizing
enzyme, is involved in hydroxylation of a large number ofAnnotation
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Fig. 1. Functional classiﬁcation of cynomolgus liver ESTs. All non-redundant ESTs were assigned to each functional category as described in
Section 2. Biological process (A) and Molecular function (B) are shown.
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longed to the CYP2C subfamily that is important for metabo-
lism of 20% of all prescribed drugs such as tolbutamide,
phenytoin, and warfarin [21]. Fifty-two ESTs belonged to
the CYP3A subfamily. In humans, genes in the CYP3A sub-family (especially CYP3A4) are essential for drug metabolism,
and are involved in the metabolism of more than half the cur-
rently prescribed drugs. Moreover, human CYP3A4 and
CYP3A5 occupy more than half of the total CYP protein
content in liver [20], contributing substantially overall drug
Table 2
Cynomolgus ESTs highly homologous to human drug-metabolizing
enzyme families, CYP, UGT, GST, SULT, and FMO
Family Contig
number
Number
of ESTs
Accession
number
Matched human
cDNA
CYP 18729 89 NM_0007700 CYP2C8
12912 38 NM_017460 CYP3A4
463 30 NM_000106 CYP2D6
19109 21 NM_000769 CYP2C19
19111 14 NM_000771 CYP2C9
12910 14 NM_000777 CYP3A5
19262 13 NM_000773 CYP2E1
7671 8 NM_023944 CYP4F12
8451 3 NM_000775 CYP2J2
8410 1 NM_000778 CYP4A11
UGT 15423 75 NM_001074 UGT2B7
2531 41 NM_019093 UGT1A3
15424 30 NM_050394 UGT2B28
GST 19270 9 NM_145740 GSTA1
14165 8 NM_000846 GSTA2
9619 7 NM_000851 GSTM5
1616 7 NM_145792 MGST1
19167 3 NM_004832 GSTO1
17697 2 NM_145870 GSTZ1
SULT 10631 10 NM_001055 SULT1A1
19266 2 NM_001054 SULT1A2
3203 1 NM_006588 SULT1C2
FMO 10051 20 NM_001002294 FMO3
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human CYP2D6. In the human genome, three CYP2D genes
are present including one functional CYP2D gene (CYP2D6)
and two pseudogenes (CYP2D7 and CYP2D8). CYP2D6
accounts for 5% of the total hepatic CYP content and is
responsible for the metabolism of 25% of all drugs oxidized
by CYPs [20]. In cynomolgus monkeys, CYP2D17, which is
highly homologous to human CYP2D6, has been isolated
[22]. Meanwhile, marmoset is known to have two functional
CYP2Ds with diﬀerent metabolic properties, CYP2D19 and
CYP2D30 [23]. Further in-depth analysis of our EST clones
could reveal whether CYP2D17 is the only CYP2D gene ex-
pressed in cynomolgus monkey liver. Characterization of these
CYP EST clones is currently in progress, such as full-length
sequencing, tissue expression patterns, and metabolic assays,
the outcome of which has been partly published [24,25].
Clusters for other drug-metabolizing enzymes of UGT,
GST, SULT, and FMO families contained 146, 36, 13, and
20 ESTs, respectively (Table 2). UGT, a phase II drug-metab-
olizing enzyme, catalyzes the conjugation of various drugs to
assist drug excretion and is composed of UGT1A, UGT2A,
and UGT2B subfamilies in humans. The 146 ESTs for the
UGT family were grouped into three clusters. Forty-one
EST sequences were highly homologous to human UGT1A3.
The UGT1A gene locus contains 13 distinct ﬁrst exons (pro-
moters) followed by exons 2–5 that are shared among all 13
transcripts, giving rise to nine diﬀerent proteins (four pseudo-
genes) in humans [26]. Considering that these ESTs were 3 0
cDNAs, the 41 EST clones possibly encode multiple UGT1A
genes. Because only four UGT1A genes have been identiﬁed
for macaques, further sequence analysis of these UGT1A ESTs
could lead to the identiﬁcation of novel UGT1A genes in thislineage. Seventy-ﬁve and 30 ESTs matched human UGT2B7
and UGT2B28, respectively. Initial full-length sequencing of
the UGT2B EST clones revealed that the clones contained
the UGT2B33 cDNA (GenBank Accession No. AB371703)
newly identiﬁed in cynomolgus monkeys as well as the previ-
ously identiﬁed cDNAs for cynomolgus UGT2B9, UGT2B18,
UGT2B19, UGT2B20, UGT2B23, and UGT2B30 (GenBank
Accession Nos. U91582, AF016310, AF112112, AF072223,
AF112113, and AF401657, respectively). In contrast to
UGT1A, UGT2B genes have been frequently duplicated in
many mammalian lineages [26]; therefore, some of these
UGT2Bs are possibly lineage-speciﬁc genes as discussed below.
Other EST sequences were highly homologous to six human
genes, two genes, and one gene in the GST, SULT, and FMO
families, respectively (Table 2). GST is another phase II en-
zyme, catalyzing the conjugation of electrophilic substrates
to glutathione and is composed of at least 16 genes for cyto-
solic, mitochondrial, and microsomal GSTs in humans [27].
SULT is also a gene family comprising at least 10 human
genes, catalyzing sulfate conjugation of a wide variety of drugs
[28]. FMO is a family of ﬂavoproteins, catalyzing oxygenation
of various drugs containing sulfur, nucleophilic nitrogen, and
phosphorus heteroatoms [29]. Full-length sequencing and
functional characterization of these EST clones are currently
under investigation, by which novel genes could be identiﬁed
because limited numbers of genes have been identiﬁed for these
enzymes in monkeys. These results suggest that our EST-
sequencing approach successfully identiﬁed a number of
cDNA clones for various drug-metabolizing enzymes in mon-
keys.3.4. Identiﬁcation of lineage-speciﬁc genes
In order to better utilize monkeys as an animal model, it is
essential to understand similarities or diﬀerences in genes ex-
pressed between monkeys and humans. The EST data should
provide essential information on lineage-speciﬁc genes and
transcripts. To identify macaque-speciﬁc transcripts, 27959
3 0 ESTs were analyzed by either a genome- or cDNA-based ap-
proach. In the genome-based approach, we found 77 EST clus-
ters, for which at least a part of the sequences were located
outside human-macaque alignable regions. In the cDNA-
based approach, we identiﬁed 12 clusters containing >10 ESTs
that were unmatched to any human RefSeq genes according to
BLASTN (cut-oﬀ = 1.0e100). Clones available for the 10
remaining candidate clusters after subsequent manual inspec-
tion, along with clones for the 29 clusters randomly selected
from 77 candidates in the genome-based approach, were sub-
jected to full-length sequencing (excluding 1 overlapping
clone). Sequence analysis of these 38 clones conﬁrmed that
nine clones contained lineage-speciﬁc candidate genes.
Of these, six clones matched to human RefSeq sequences
(Table 3): two clones lack a portion of human genome
sequence and the other four matched to more than one
member of a gene family. Thus, these four clones were poten-
tially lineage-speciﬁc genes and were further characterized as
described below.
One candidate clone (Qlv-U097A-G10) encoded CYP2C76
with a relatively low homology (80%) to members of the
human CYP2C subfamily, CYP2C8, CYP2C9, CYP2C18,
and CYP2C19 (Table 3). The extent of homology was much
lower than those for other ESTs (95%). Our characterization
Table 3
Potential lineage-speciﬁc ESTs in cynomolgus monkey
Clone ID GenBank
Accession number
Nucleotide
(bp)
ORFa
(Number of
amino acids)
Cynomolgus
sequence
The most highly
homologous human
RefSeq cDNAs
Genome- or
cDNA-based
approach
Aligned
location
Novel member of gene family
Qlv-U042A-F11 AB362497 1637 454 None CFH, CFHR3/4 Genome/cDNA Intergenic
Qlv-U097A-G10 AB362507 1986 489 CYP2C76 CYP2C8/9/18/19 cDNA Intergenic
Qlv-U346A-B11b AB371605 1758 472 CYP2A23 CYP2A6/7/13 cDNA Intergenic
Qlv-U405A-G11 AB362508 2225 528 UGT2B19 UGT2B4 cDNA Intergenic
Partially unmatched to human genome
Qlv-U244A-C6b AB362499 1612 305 None TSPAN12 Genome Intergenic
Qlv-U258A-D7b AB362500 1984 89 None SS18L1 Genome Intergenic
Unmatched to human genome
Qlv-U050A-D10 AB362503 1700 34 None None Genome Intron
Qlv-U295A-A3 AB362504 2278 118 None None Genome Intergenic
Qlv-U389A-C1 AB362506 2043 90 None None Genome Intergenic
aThe longest ORF was selected.
bTranscript variants with diﬀerent exon-intron structure from human homologs.
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RNA, protein, and genomic level revealed that this CYP2C
did not have any human ortholog because the corresponding
genes were not found in the human genome [24]. Moreover,
this CYP2C76 was at least partly responsible for lineage dif-
ferences in drug metabolism [30]. These results conﬁrmed that
our comparative genomic approach succeeded in identifying
macaque-speciﬁc transcripts that are absent in humans.
One clone (Qlv-U405A-G11) identiﬁed as a lineage-speciﬁc
candidate contained the cDNA for UGT2B19 previously re-
ported [31]. Cynomolgus UGT2B19 as well as UGT2B30
cDNAs were both highly homologous (92%) to human
UGT2B4 cDNA [32]. A phylogenetic comparison (Fig. 2) indi-
cated that the 1-to-1 orthologous relationship to the human
UGT2Bs could not be determined for these cynomolgus
UGT2Bs, raising the possibility that UGT2B19 might be a
lineage-speciﬁc gene. UGT2B19 is expressed in cynomolgus
monkey liver and prostate and has enzymatic activity to
xenobiotics (1-naphthol) and steroids (testosterone) [31]. The
UGT2B subfamily consisted of a number of member genes
including a lineage-speciﬁc candidate [26], suggesting that
UGT2B19 and other functional UGT2B enzymes in cynomol-
gus monkeys contribute not only to overall drug metabolism inhUGT2B11
hUGT2B28hUGT2B10
mUGT2B19mUGT2B30
hUGT2B4
hUGT2B15
hUGT2B17
mUGT2B20
hUGT2B7
mUGT2B18
mUGT2B23
mUGT2B33
mUGT2B9
0.1
Fig. 2. A phylogenetic comparison of UGTs between macaque and
human. The phylogenetic tree was based on amino acid sequence using
the Clustal W program. Deduced amino acid sequences were used for
cynomolgus monkeys (m) and human (h).monkey liver but also possibly to diﬀerences in drug metabo-
lism.
Another lineage-speciﬁc candidate clone (Qlv-U346A-B11)
was cynomolgus CYP2A23 variant (tentatively named CY-
P2A23v), containing exons 1–8 with a partial intron 8 sequence
and thus, lacking the entire exon 9 as compared to a complete
CYP2A23 transcript. CYP2A23 and another cynomolgus
CYP2A, CYP2A24, were both highly homologous (95%) to
the three human CYP2As, speciﬁcally CYP2A6, CYP2A7,
and CYP2A13, indicating the diﬃculty in determining the
orthologous relationship of CYP2A23 and CYP2A24 to
human CYP2As [25]. This novel CYP2A23 transcript variant
encodes a protein of 472 amino acids and lacks a part of a
heme-binding region essential for CYP proteins (Fig. 3). The
protein generated from this transcript, therefore, might not
function as a drug-metabolizing enzyme. A similar transcript
variant was also identiﬁed for CYP2C76 and UGT2B19 (data
not shown). It remains to be determined whether the presence
of these transcripts lacking a functional domain is limited to
the animals that provided liver samples for the cDNA library
construction and what roles these transcript variants play in
drug metabolism.
Other than those for drug metabolism, one lineage-speciﬁc
candidate (Qlv-U042A-F11) had high sequence homology to
complement factor H (CFH) family genes in humans (Table 3).
CFH (also called Factor H), an important complement regula-
tor, forms a gene family along with CFH-related proteins
(CFHL1-5) in humans [33]. This macaque transcript contained
an open reading frame (ORF) of 454 amino acids. CFH and
other genes important for immune response and T cell-medi-
ated immunity such as immunoglobulin-like genes and MHC-
related genes have been identiﬁed in macaques as the genes
that went under positive selection [13,14,34], and thus, our
ﬁnding of lineage-speciﬁc CFH-like sequence in macaques is
not surprising. Further analysis of this CFH-like sequence
indicated that the ﬁrst 19 amino acids and the remaining ami-
no acids were highly similar to CFH-related proteins (CFHR3
and CFHR4) and CFH in humans, respectively (data not
shown), raising the possibility that this novel transcript might
be a hybrid of CFH and CFH-related genes. In humans, a hy-
brid transcript of CFH and CFHR1 has been identiﬁed and
implicated in atypical haemolytic uraemic syndrome [35].
Fig. 3. Alignment of the amino acid sequences deduced from cynomolgus monkey (m) and human (h) CYP2A cDNAs. The sequences were aligned
using the Clustal W program. Asterisks and dots under the sequences indicate identical amino acids and conservatively unchanged amino acids,
respectively. A black line under the amino acid sequences indicates the putative heme-binding region. The CYP2A23 variant (mCYP2A23v) newly
identiﬁed lacks half of the putative heme-binding region.
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identiﬁcation successfully identiﬁed potential lineage-speciﬁc
genes or transcripts, possibly relevant to the immune system.
Further investigation of other ESTs should help make better
use of the macaque for immunological studies.
Three candidate genes were unmatched to any human Ref-
Seq sequence, and thus could be apparent lineage-speciﬁc
genes (Table 3). The two candidate genes (Qlv-U295A-A3
and Qlv-U389A-C1) reside in intergenic regions of the maca-
que genome, which might be novel genes in monkeys. This
was supported by the fact that these two sequences did not
match any human ESTs by BLAST (data not shown). The
two transcripts contained relatively small ORFs (<100 amino
acids). Transcripts with small ORFs have been identiﬁed in
mice and humans, some of which could be actually translated
in vitro [36,37]. Alternatively, these mRNAs might be func-
tioning as non-coding RNAs. A large proportion of transcripts
are non-coding RNAs, including those having essential func-
tions in transcriptional and translational control [38,39].4. Conclusion
The data presented here provide an overview of genes ex-
pressed in cynomolgus liver to investigate liver physiology
for macaques. ESTs for genes encoding a variety of drug-metabolizing enzymes hold great promise in deepening our
understanding of drug metabolism in monkeys, which in turn
helps to elucidate lineage diﬀerences between monkeys and hu-
mans. Indeed, our characterization of CYP2C ESTs has iden-
tiﬁed lineage-speciﬁc CYP2C76, which is responsible for
lineage diﬀerences in drug metabolism [24,30]. Furthermore,
the ESTs generated in this study can be a resource for the pro-
duction of microarrays. Given that our cDNA library was gen-
erated with RNAs from only three animals, the EST
sequencing using the library originated from the RNA samples
of more animals would be useful for the identiﬁcation of the
allelic variants expressed in liver.
Many drug-metabolizing enzyme genes are conﬁned to gene
families, many of which have been subjected to gene duplica-
tion or gene loss during evolution, resulting in family size dif-
ferences [40]. This indicates that lineage-speciﬁc genes could be
identiﬁed for gene families even between evolutionarily close
lineages such as monkeys and humans. Moreover, physio-
logical diﬀerences should partly result from diﬀerences at the
transcriptional level, for example, by alternative splicing and
non-coding RNAs [41]. Further investigation of our EST data
will lead to the identiﬁcation of lineage-speciﬁc transcripts gen-
erated by alternative splicing and lineage-speciﬁc gene gain/
loss, as the eﬀorts for identifying such transcripts have suc-
ceeded partly in macaques [9,13]. The identiﬁed lineage-speciﬁc
transcripts and genes will help lead to a better understanding
Y. Uno et al. / FEBS Letters 582 (2008) 351–358 357of the physiological diﬀerences between monkeys and humans,
leading to more eﬃcient utilization of monkeys as an animal
model.
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